검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-GPC3 T Cells |
Overview Company | CARsgen Therapeutics Co., Ltd. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.. Our preclinical studies demonstrated the potential of chimeric antigen receptor (CAR)-glypican-3 (GPC3) T-cell therapy for hepatocellular carcinoma (HCC). We report herein the first published results of CAR-GPC3 T-cell therapy for HCC. In two prospective phase I studies, adult pat… |
Toxicology CRS | grade 1 |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 50.0% |
Clinical Result source | ClinicalTrials.gov NCT04377932 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-GPC3 T Cells |
Overview Company | CARsgen Therapeutics Co., Ltd. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.. Our preclinical studies demonstrated the potential of chimeric antigen receptor (CAR)-glypican-3 (GPC3) T-cell therapy for hepatocellular carcinoma (HCC). We report herein the first published results of CAR-GPC3 T-cell therapy for HCC. In two prospective phase I studies, adult pat… |
Toxicology CRS | grade 1 |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 50.0% |
Clinical Result source | ClinicalTrials.gov NCT04377932 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교